SAN DIEGO , Sept. 28, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the closing of its underwritten public offering of 2,530,000

SAN DIEGO , Sept. 25, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the pricing of its underwritten public offering of 2,200,000

SAN DIEGO , Sept. 24, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that it intends to offer $200.0 million of its common stock in

Lung function improvement occurred rapidly following a single dose of etokimab, with an 8 percent increase in FEV1 over placebo at Day 2 FEV1 improvement was sustained throughout the interim analysis period, with an 11 percent increase over placebo at Day 64 Blood eosinophil reduction was

Top-line Phase 2a Data from Etokimab (ANB020) in Eosinophilic Asthma Expected in Third Quarter of 2018 Etokimab Clinical Development Program Expanded to Include Chronic Rhinosinusitis with Nasal Polyps Commercial Considerations Led to Deprioritization of Further AnaptysBio-Sponsored Clinical

SAN DIEGO , Aug. 06, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will

SAN DIEGO , May 30, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will

Blood eosinophil level reduction consistent with clinical efficacy in ANB020 Phase 2a atopic dermatitis trial ANB020-mediated eosinophil reduction is aligned with genotypic data from prior human IL-33 loss-of-function studies Favorable safety, pharmacokinetics and pharmacodynamics observed in

Positive Phase 2a Proof-of-Concept Data Reported from ANB020 Trials in Atopic Dermatitis and Peanut Allergy Top-Line Phase 2a Data from ANB020 in Eosinophilic Asthma Expected in the Third Quarter of 2018 SAN DIEGO , May 08, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc.

SAN DIEGO , May 01, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that clinical data for its ANB020 and ANB019 programs will be